Search results
Results: 88
Number of items: 88
-
Steuten, J., Bos, A. V., Kuijper, L. H., Claireaux, M., Olijhoek, W., Elias, G., Duurland, M. C., Jorritsma, T., Marsman, C., Paul, A. G. A., Garcia Vallejo, J. J., van Gils, M. J., Wieske, L., Kuijpers, T. W., Eftimov, F., van Ham, S. M., ten Brinke, A., & T2B Consortium (2023). Distinct dynamics of antigen-specific induction and differentiation of different CD11c+Tbet+ B-cell subsets. Journal of Allergy and Clinical Immunology, 152(3), 689-699.e6. https://doi.org/10.1016/j.jaci.2023.02.020 -
van Kempen, Z. L. E., Stalman, E. W., Steenhuis, M., Kummer, L. Y. L., van Dam, K. P. J., Wilbrink, M. F., Ten Brinke, A., van Ham, S. M., Kuijpers, T., Rispens, T., Eftimov, F., Wieske, L., Killestein, J., & T2B! immunity against SARS-CoV-2 study group (2023). SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 94(4), 280-283. https://doi.org/10.1136/jnnp-2022-330100 -
van Osch, T. L. J., Steuten, J., Nouta, J., Koeleman, C. A. M., Bentlage, A. E. H., Heidt, S., Mulder, A., Voorberg, J., van Ham, S. M., Wuhrer, M., ten Brinke, A., & Vidarsson, G. (2023). Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages. Platelets (London), 34(1), Article 2129604. https://doi.org/10.1080/09537104.2022.2129604 -
Stalman, E. W., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases, 81(12), 1757-1766. https://doi.org/10.1136/ard-2022-222904
-
Boekel, L., Besten, Y. R., Hooijberg, F., Wartena, R., Steenhuis, M., Vogelzang, E., Leeuw, M., Atiqi, S., Tas, S. W., Lems, W. F., van Ham, S. M., Eftimov, F., Stalman, E. W., Wieske, L., Kuijpers, T. W., Voskuyl, A. E., van Vollenhoven, R. F., Gerritsen, M., Krieckaert, C., ... Wolbink, G. (2022). SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. The Lancet. Rheumatology, 4(11), e747-e750. https://doi.org/10.1016/S2665-9913(22)00221-1
-
Boekel, L., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. The Lancet. Rheumatology, 4(6), e417-e429. https://doi.org/10.1016/S2665-9913(22)00102-3
-
Wieske, L., Tas, S. W., Takkenberg, R. B., Verstegen, N. J. M., Zwinderman, K. A. H., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. The Lancet. Rheumatology, 4(5), e338-e350. https://doi.org/10.1016/S2665-9913(22)00034-0
Page 4 of 9